Global Radiopharmaceutical Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Radiopharmaceutical market size was valued at US$ 6871 million in 2024 and is forecast to a readjusted size of USD 11060 million by 2031 with a CAGR of 7.1% during review period.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.
This report is a detailed and comprehensive analysis for global Radiopharmaceutical market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceutical market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (USD/Dose), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radiopharmaceutical
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radiopharmaceutical market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Radiopharmaceutical market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Market segment by Application
Oncology
Cardiology
Other
Major players covered
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radiopharmaceutical product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Radiopharmaceutical, with price, sales quantity, revenue, and global market share of Radiopharmaceutical from 2020 to 2025.
Chapter 3, the Radiopharmaceutical competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radiopharmaceutical breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Radiopharmaceutical market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Radiopharmaceutical.
Chapter 14 and 15, to describe Radiopharmaceutical sales channel, distributors, customers, research findings and conclusion.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.
This report is a detailed and comprehensive analysis for global Radiopharmaceutical market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceutical market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2020-2031
Global Radiopharmaceutical market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (USD/Dose), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radiopharmaceutical
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radiopharmaceutical market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Radiopharmaceutical market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Market segment by Application
Oncology
Cardiology
Other
Major players covered
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radiopharmaceutical product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Radiopharmaceutical, with price, sales quantity, revenue, and global market share of Radiopharmaceutical from 2020 to 2025.
Chapter 3, the Radiopharmaceutical competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radiopharmaceutical breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Radiopharmaceutical market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Radiopharmaceutical.
Chapter 14 and 15, to describe Radiopharmaceutical sales channel, distributors, customers, research findings and conclusion.
Table of Contents
117 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Radiopharmaceutical by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
